AD8.5                                Other Safety Findings

 

AD8.5.1                                ADE Incidence Tables

 

BODY SYSTEM / ADVERSE EXPERIENCE

Bupropion sustained-release Dosing Group

 

150 mg/d

(N=147)

300 mg/d

(N=147)

Placebo

(N=150)

Vomiting

2.0%

3.4%

2.0%

Toothache/Tooth Abscess

0.7%

1.4%

1.3%

Flatulence

2.0%

2.7%

2.7%

Anorexia

3.4%

4.8%

2.7%

Dyspepsia

4.8%

2.7%

5.3%

Body (General)

Headache

23.1%

25.9%

18.0%

Chest Pain

1.4%

3.4%

0.7%

Asthenia

2.7%

1.4%

1.3%

Back Pain

2.0%

2.7%

2.7%

Fever

0.7%

0%

0.7%

Neck Pain

1.4%

0.7%

0.7%

Accidental Injury

3.4%

0.7%

1.3%

Abdominal Pain

4.1%

3.4%

0.7%

Respiratory System Disorders

Pharyngitis

1.4%

2.7%

2.0%

Rhinitis

10.2%

4.1%

11.3%

Sinusitis

2.7%

3.4%

2.7%

Respiratory Complaints

0%

0.7%

0%

Laryngitis

0.7%

1.4&

0.7%

Skin and Appendages Disorders

Sweating

2.0%

4.1%

2.0%

Rash

1.4%

2.0%

2.0%

Pruritus

2.0%

0%

1.3%

Urticaria

1.4%

1.4%

0%

Acne

1.4%

2.7%

0%

Back a Page
Next Page
Back to Wellbutrin SRŪ NDA Index Page
Back to Main Index

1